

Cover Story
Health Equity
By Matthew Bin Han Ong
Every cancer center seeking to obtain (or keep) an NCI designation will soon have to present a plan for increasing the diversity of their faculty and workforce.
In Brief


Funding Opportunities
Clinical Roundup
Drugs & Targets


NCI Trials


NCI Trials for December 2021
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - CBER Director Vinay Prasad dared to “say no to drugs”
- J. Craig Venter’s work was foundational to cancer advancement of the past 25 years
- Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)

















